**Core tip:** The study is one of the first projects to use a 10-years nationally linked dataset. The results highlight a new epidemic of diabetes in the United States. It addresses the impact of diabetes on cardiovascular disease and all-cause mortality. The study is also one of the first studies to explore the association between glucose lowering drug use and health outcomes using health survey data from the real-world.

INTRODUCTION
============

Diabetes mellitus (DM) is the seventh leading cause of death in the United States. Of 2543279 death certificates from all-causes in 2010, 2.9% of deaths (*n* = 73932) clinically listed DM as the main cause of death, and more than 9% of deaths (*n* = 234051) were attributable to DM as a comorbid cause of death in the United States. It is estimated that more than 1.4 million Americans are diagnosed with DM every year. In 2012, 29.1 million Americans, or 9.3% of the population, had DM. Of the 29.1 million, 21 million were diagnosed, and 8.1 million were undiagnosed\[[@B1]\]. A similar increased prevalence of DM has been estimated worldwide\[[@B2]\]. It is clear that DM has posed a serious public health problem in the United States and in the world\[[@B1]-[@B4]\], not only because DM is a leading cause of death, but also DM is a significant risk factor for cardiovascular disease (CVD). CVD is the number one killer of the Americans\[[@B5]-[@B10]\]. Although the overall trend in the prevalence of DM and its impact on risk of CVD have been examined by several studies, some were limited to their small sample sizes\[[@B11]\], some were limited to their study designs \[such as findings from the Behavior Risk Factor Surveillance Systems that are conducted using a telephone survey with a very low response rate (\< 40%)\]\[[@B12]\], and some were limited to a cross-sectional analysis design\[[@B7],[@B13]\]. Furthermore, patterns of antidiabetic treatment and its impact on long-term health outcomes are less known. In the present study, we aimed to examine the trend of DM, and the impact of DM on CVD (hypertension, coronary heart disease and stroke), and risk of mortality from CVD and all-cause using a nationally representative sample in the United States. Findings from the study may add new evidence of the burdens of DM to the body of the literatures, the patterns of antidiabetic medications usage, and the magnitudes of DM and drug use on all-cause and CVD mortalities.

MATERIALS AND METHODS
=====================

Participants ages 18 years and older in the 2000-2009 National Health Interview Surveys (NHIS) were included in the study. The NHIS has been conducted annually since 1960 by the United States National Center for Health Statistics (NCHS), which is a part of the Centers for Disease Control and Prevention (CDC)\[[@B14]\]. NHIS is a cross-sectional household interview survey that serves as the principal source of information on the health of the noninstitutionalized civilian population of the United States\[[@B15]\]. Uniform sampling and interviewing processes for core variables are continuous throughout each year's survey. The sampling plan follows a multistage area probability design that permits the representative sampling of households and non-institutionalized groups. In NHIS, one adult per household is randomly chosen to participate in a completed interview from approximately 30000 households containing about 85500 persons, of them about 30000 adults ages 18 and older. Participants' vital status (alive or deceased) are followed yearly and linked to death certificates in the National Death Index system (NHIS-Mortality Linked File). This Linked File provides an important opportunity for health professionals to estimate the risk of mortality prospectively on the basis of the NHIS participants' baseline characteristics\[[@B14]\]. In the present study, we applied the most recently released NHIS-Mortality Linked File, which had follow-up information for subjects who participated in NHIS in and before 2009, and followed up through the end of 2011 (December 31, 2011). We examined the past one decade trend of DM between 2000 and 2009, and risk of mortality in patients with DM. Of total 287530 participants ages 18 and older, we excluded 15381 who had missing information on prevalent DM status at baseline (*n* = 237), and those who were lost to follow-up (*n* = 15144) during the course of follow-up between 2000 and 2011, yielding a final analytic sample of 272149 adults (94.7% = 272149/287530). To examine the patterns of medication use in patients with DM, we further linked the study sample at individual participant's level with the Medical Expenditure Panel Surveys (MEPS)\[[@B16]\]. The NHIS, NHIS-Mortality Linked File and MEPS have been approved by the Institutional Review Board of the United States CDC NCHS and are available through the NCHS\[[@B14]\]. The present analysis has been approved by Drexel University Institutional Review Board (\# 1605004544).

Two groups of health outcomes in patients with and without DM were examined: (1) all-cause mortality; and (2) CVD mortality. Mortality data were defined using ICD-10: Heart disease (ICD10: I00-I09, I11, I13, I20-I51), cerebrovascular disease (ICD10: I60-I69). CVD includes the two major forms of heart disease and cerebrovascular disease (ICD10: I00-I09, I11, I13, I20-I51 and ICD10: I60-I69). Predictors and covariates included: (1) demographic factors: Age, gender, race/ethnicity and education attainments (\< high-school graduate, high-school graduate, and ≥ college); (2) lifestyle related factors: Body mass index \[BMI, calculated by weight (kg)/height (m^2^)\], cigarette smoking (never smoked, formerly smoked, or currently smoker), alcohol consumption (not a drinker: \< 12 drinks in entire life, former drinker: No drinks in previous year, and current drinker), and physical activity. BMI was classified into four groups on the basis of the World Health Organization (WHO) definition (underweight: \< 18.5, normal weight: 18.5-24.9, overweight: 25-29.9, and obese: ≥ 30 kg/m^2^). Physical activity status was grouped on the basis of current guidelines (active: ≥ 150 min per week of moderate-intensity equivalent leisure-time aerobic activity; insufficiently active: 10-149 min per week of moderate-intensity equivalent leisure-time aerobic activity); (3) CVD related chronic conditions: Hypertension, coronary heart disease (CHD) and stroke. Baseline CVD includes patients who had CHD and/or stroke. The baseline chronic conditions were classified by participants' self-reports of diagnoses made by a doctor or health professional; and (4) DM, oral glucose-lowering medication and insulin use were classified according to DM patients' prescription records.

Statistical analysis
--------------------

A serial analysis was conducted to test the study hypotheses and fit the time-events prediction models. The first group analysis included the basic characteristics description of the study participants and tested gender differences using univariate analysis, including *t* test for continuous variables, and *χ*^2^ tests for categorical variables. Changes in the prevalence of DM from 2000 to 2009 by sex and ages (18-54, 55-64, 65-74 and ≥ 75) were tested using simple linear regression models. The second group analysis involved estimates of mortality rates (per 1000 person-year) from all-cause, heart disease, cerebrovascular disease, and total CVD. We used Poisson regression to calculate mortality per person years. The third group analysis estimated the hazard ratios of DM (yes/no) for the risk of mortality from all-cause, heart disease, cerebrovascular disease, and total CVD using Cox's proportional hazard regression models. In the analysis, five multivariate adjusted Cox's models were performed by gender. Model 1 adjusted for age (years) and race/ethnicity (NH-White, NH-Black, Hispanics, and other groups). Model 2 adjusted for age, race/ethnicity and education level (\< higher school, high school, and ≥ college). Model 3 adjusted for the covariates used in Model 2 plus three behavioral factors (smoking, alcohol consumption and physical activity). Model 4 adjusted for the covariates used in Model 3 plus hypertension. Because patients with CVD at baseline may have an increased risk of mortality, we excluded those patients in Model 5 and adjusted the same covariates as used in Model 4. Interactions of gender and DM on risk of mortality were tested using SAS Proc GENMOD. The fourth group analysis involved in estimates of the prevalence of glucose lowering medication and insulin use. We examined hazard ratios of monotherapy and combinations of glucose lowering medication and insulin use for the risk of mortalities compared to those without antidiabetic medication use. In the last group analysis, we compared baseline differences in 5 preventable factors' age-race-adjusted standardized rates (education level, as a marker for economic status, smoking, physical activity, BMI and hypertension) between males and females using logistic regression in order to explain a potential gender difference in the relative risk of all-cause and CVD mortality in patients with DM.

All data analyses were performed using SAS version 9.3, with complex sample modules that take the sample design of NHIS, including stratification, clustering and weight into consideration (SAS Institute, Cary, NC). Statistical significance was determined for a two-sided test at a *P* value \< 0.05.

RESULTS
=======

Baseline characteristics of the study participants
--------------------------------------------------

Of 272149 subjects participated in 2000-2009 NHIS, 22305 (8.2%) had diabetes (male: 9892, and female: 12413). The prevalence of DM significantly increased from 2000 to 2009 in all age groups for males and females (*P* \< 0.001) (Figure [1A](#F1){ref-type="fig"}). The annual increase rates (per 1000) were 2.27, 4.54, 5.07, and 7.56 for male aged 18-54, 55-64, 65-74 and ≥ 75, respectively (test for linear trend, all *P* \< 0.01). The corresponding values in females were 2.19, 6.76, 7.00 and 6.12, respectively (*P* \< 0.01). Females had 1.49 times higher annual increase in those aged 55-64, and 1.38 higher in those aged 65-74 compared to males (Figure [1B](#F1){ref-type="fig"}). There were significant differences in demographic, behavior factors and medical conditions between those with and without DM in males and females (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

###### 

Baseline characteristics of participants, United States National Health Interview Surveys 2000-2009

                          **Male**   **Female**                                                                                              
  ----------------------- ---------- ------------ -------- ------ ------ -------- ----------- ------- ------ -------- ------ ------ -------- -----------
  Age, mean, yr           44.9                    (0.10)   60.3          (0.14)   \< 0.0001   46.6           (0.1)    60.7          (0.16)   \< 0.0001
  Race/ethnicity                                                                                                                             
  NH-White                71683      74.5         (0.25)   6062   70.9   (0.55)   \< 0.0001   89088   73.8   (0.25)   6782   66.6   (0.55)   \< 0.0001
  NH-Black                13345      10.4         (0.18)   1712   14.2   (0.40)               21517   12.5   (0.20)   2923   19.2   (0.46)   
  Hispanics               19251      10.7         (0.17)   1646   10.4   (0.36)               23779   9.8    (0.15)   2260   10.7   (0.36)   
  Others                  5228       4.4          (0.10)   472    4.5    (0.25)               5953    3.9    (0.08)   448    3.4    (0.21)   
  Education                                                                                                                                  
  Less than HS            19941      15.3         (0.18)   2682   24.0   (0.52)   \< 0.0001   25377   15.0   (0.16)   4066   28.8   (0.50)   \< 0.0001
  HS Graduated            30474      28.0         (0.21)   2887   30.6   (0.58)               39612   28.4   (0.19)   3873   33.1   (0.54)   
  ≥ College               58314      56.6         (0.30)   4231   45.3   (0.58)               74451   56.5   (0.27)   4370   38.1   (0.53)   
  Smoking status                                                                                                                             
  No smoker               54430      49.6         (0.24)   3667   36.7   (0.58)   \< 0.0001   87384   60.8   (0.21)   7344   58.2   (0.51)   \< 0.0001
  Former smoker           26644      24.9         (0.19)   4293   44.6   (0.60)               24800   19.1   (0.14)   3075   26.4   (0.47)   
  Current smoker          27507      25.5         (0.19)   1834   18.7   (0.46)               27211   20.1   (0.16)   1893   15.4   (0.35)   
  Alcohol consumption                                                                                                                        
  Never                   16415      14.3         (0.19)   1660   16.5   (0.43)   \< 0.0001   41116   27.0   (0.23)   5159   39.7   (0.55)   \< 0.0001
  Former                  15028      13.8         (0.15)   3348   34.0   (0.61)               19335   14.1   (0.13)   3389   28.2   (0.51)   
  Current                 75204      71.8         (0.22)   4668   49.5   (0.62)               77255   58.9   (0.25)   3670   32.1   (0.54)   
  Exercise                                                                                                                                   
  Inactive                38394      34.5         (0.32)   4485   47.0   (0.62)   \< 0.0001   55965   38.9   (0.29)   6416   55.2   (0.62)   \< 0.0001
  Insufficiently active   27605      27.2         (0.18)   2178   24.6   (0.50)               40073   31.0   (0.18)   2724   25.1   (0.49)   
  Sufficiently active     38609      38.3         (0.26)   2473   28.3   (0.59)               38637   30.0   (0.22)   2158   19.8   (0.45)   
  BMI, kg/m^2^                                                                                                                               
  Overweight              46884      43.5         (0.18)   3595   36.2   (0.55)   \< 0.0001   38254   28.1   (0.15)   3250   28.0   (0.45)   \< 0.0001
  Obesity                 24128      22.4         (0.17)   4372   46.1   (0.59)               31193   22.4   (0.15)   6168   52.8   (0.53)   
  Medical condition                                                                                                                          
  Hypertension            25582      23.7         (0.19)   6501   66.3   (0.56)   \< 0.0001   35594   25.6   (0.17)   8662   69.8   (0.48)   \< 0.0001
  Coronary heart Dis      7020       6.6          (0.09)   2598   27.2   (0.48)   \< 0.0001   6435    4.7    (0.07)   2450   20.3   (0.41)   \< 0.0001
  Stroke                  2243       2.1          (0.05)   956    9.6    (0.30)   \< 0.0001   3244    2.4    (0.05)   1233   10.0   (0.32)   \< 0.0001
  CVD                     8434       7.8          (0.10)   3019   31.4   (0.51)   \< 0.0001   8699    6.4    (0.09)   3109   25.6   (0.43)   \< 0.0001

No. = Observed number;

Rate for weighted rate using SAS for complex survey;

T test for continuous variable, and *χ*^2^ test for categorical variables. Education ≥ College including those with associate degrees. Overweight: Body mass index (BMI) 25 to 29.9 kg/m^2^. Obesity: BMI ≥ 30 kg/m^2^. CVD: Cardiovascular disease; DM: Diabetes mellitus; SEP: Standard error of proportion.

![The Burden of diabetes in the United States. A: Prevalence (%) of diabetes by age and gender, United States NHIS 2000-2009; B: Annual average increase rate (per 1000) of diabetes by age and gender, United States NHIS 2000-2009. NHIS: National Health Interview Surveys.](WJD-7-449-g001){#F1}

![Prevalence (%) of comobid hypertnesion, coronary heart disease, strroke and cardiovascular disease in patients with and without diabetes mellitus, United States National Health Interview Surveys 2000-2009. HTN: Hypertnesion; CHD: Coronary heart disease; CVD: Cardiovascular disease; DM: Diabetes mellitus; NHIS: National Health Interview Surveys.](WJD-7-449-g002){#F2}

Mortality from all-cause and CVD in patients with DM vs those without DM
------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} shows that mortality from all-cause, heart disease, cerebrovascular disease (CBVD) and CVD increased with age in subjects with or without DM. However, patients with DM had significantly higher mortality than those without DM in both males and females, except for CBVD in males aged 18-54.9 (*P* = 0.063), and aged ≥ 75 (*P* = 0.694), and in females aged ≥ 75 (*P* = 0.371). Figure [3A](#F3){ref-type="fig"} depicts an overall increase in all-cause mortality with increased age in males and females, but a greater increased trend for those aged ≥ 65. Similar trend for CVD mortality is shown in Figure [3B](#F3){ref-type="fig"}. Subjects without DM had a much lower mortality rate from all-cause and CVD before the age of 65 as compared to those with DM and age of 65 and older.

###### 

Mortality (per 1000 person year) from all-cause, heart disease, cerebrovascular disease and cardiovascular disease by December 31, 2011 for baseline participants with or without diabetes, United States National Health Interview Surveys 2000-2009

                  **Male**   **Female**                                                                
  --------------- ---------- ------------ ------ ----- ------- ----------- ------ ------ ------ ------ -----------
  All-cause                                                                                            
  No. of death    8363                    2278                 9485               2450                 
  Age             18-54.9    1765         2.9    317   14.1    \< 0.0001   1384   1.9    249    8.6    \< 0.0001
                  55-64.9    1271         12.5   473   27.8    \< 0.0001   989    7.6    403    21.6   \< 0.0001
                  65-74.9    1874         30.7   677   46.0    \< 0.0001   1681   18.3   693    37.6   \< 0.0001
                  ≥ 75       3453         86.5   811   103.1   \< 0.0001   5431   63.2   1105   79.3   \< 0.0001
  Heart disease                                                                                        
  No. of death    1707                    543                  1603               506                  
  Age             18-54.9    288          0.5    62    2.8     \< 0.0001   115    0.2    41     1.4    \< 0.0001
                  55-64.9    244          2.4    116   6.8     \< 0.0001   108    0.8    72     3.9    \< 0.0001
                  65-74.9    350          5.7    164   11.1    \< 0.0001   241    2.6    132    7.2    \< 0.0001
                  ≥ 75       825          20.7   201   25.6    0.032       1139   13.2   261    18.7   \< 0.0001
  CBVD                                                                                                 
  No. of death    376                     112                  621                134                  
  Age             18-54.9    50           0.1    4     0.2     0.063       58     0.1    8      0.3    0.002
                  55-64.9    38           0.4    19    1.1     \< 0.001    33     0.3    19     1.0    \< 0.0001
                  65-74.9    67           1.1    35    2.4     \< 0.001    96     1.0    34     1.8    0.003
                  ≥ 75       221          5.5    54    6.9     0.694       434    5.0    73     5.2    0.371
  CVD                                                                                                  
  No. of death    2083                    655                  2224               640                  
  Age             18-54.9    338          0.6    66    2.9     \< 0.0001   173    0.2    49     1.7    \< 0.0001
                  55-64.9    282          2.8    135   7.9     \< 0.0001   141    1.1    91     4.9    \< 0.0001
                  65-74.9    417          6.8    199   13.5    \< 0.0001   337    3.7    166    9.0    \< 0.0001
                  ≥ 75       1046         26.2   255   32.4    0.038       1573   18.3   334    24.0   \< 0.0001

*P* values were given by *χ*^2^ test. Mortality rates (per 1000) were estimated using Poisson regression. CBVD: Cerebrovascular disease; CVD: Cardiovascular disease; DM: Diabetes mellitus.

![Mortality from all-cause and cardiovascular disease by diabetes status. A: Mortality (per 1000 person year) from all-cause in patients without and with diabetes, United States NHIS 2000-2009; B: Mortality (per 1000 person year) from CVD in patients with diabetes by age and gender, United States NHIS 2000-2009. CVD: Cardiovascular disease; NHIS: National Health Interview Surveys; DM: Diabetes mellitus.](WJD-7-449-g003){#F3}

Multivariate adjusted hazard ratios of DM for risk of mortality
---------------------------------------------------------------

Of the total study sample, within an average 7.39 (SD = 3) years of follow-up, the results show that after adjustment for age and race/ethnicity, male patients with DM *vs* non-DM had 1.56 times higher risk of death from all-cause (HR = 1.56, 95%CI: 1.49-1.64), 1.72 times higher from heart disease (HR = 1.72, 95%CI: 1.53-1.93), 1.48 times higher from CBVD (HR = 1.48, 95%CI: 1.18-1.85), and 1.67 times higher from CVD (HR = 1.67, 95%CI: 1.51-1.86), respectively (Model 1, Table [3](#T3){ref-type="table"}). Similar results were observed in females. After further adjustment for the inclusion of education (Model 2), and behavior risk factors (cigarette smoking, alcohol consumption, and physical inactivity, Model 3), the corresponding HRs of DM for the risk of the mortalities remained statistically significant in patients with DM *vs* those without DM in males and in females. Model 4 shows that after a further control of the effect of hypertension, the HRs were attenuated compared to Model 3, specifically the impact of DM on the risk of death from CBVD became a borderline significance in males (*P* = 0.06). Finally, we excluded those who had heart disease and stroke at baseline (Model 5), the results show that HRs were further attenuated, except for a slight but non-significant increase in HR for death from CBVD in females.

###### 

Multivariate adjusted hazard ratios (HR, 95%CI) of diabetes mellitus for mortality from all-cause, heart disease, cerebrovascular disease and cardiovascular disease by gender

                                            **Male (*n* = 119399)**   **Female (*n* = 152750)**   **Excess HR[1](#T3FN1){ref-type="table-fn"}**                                           
  ----------------------------------------- ------------------------- --------------------------- ----------------------------------------------- ------ ------------- ----------- ------ ------
  DM *vs* non-DM                                                                                                                                                                          
  Model 1                                                                                                                                                                                 
  All-cause                                 1.56                      (1.49-1.64)                 \< 0.0001                                       1.69   (1.61-1.78)   \< 0.0001   8.3    0.02
  Heart Dis                                 1.72                      (1.53-1.93)                 \< 0.0001                                       2.02   (1.81-2.25)   \< 0.0001   17.4   0.05
  CBVD                                      1.48                      (1.18-1.85)                 0.001                                           1.43   (1.15-1.77)   0.001       -3.5   0.35
  CVD                                       1.67                      (1.51-1.86)                 \< 0.0001                                       1.85   (1.69-2.03)   \< 0.0001   10.5   0.16
  Model 2                                                                                                                                                                                 
  All-cause                                 1.54                      (1.47-1.62)                 \< 0.0001                                       1.62   (1.55-1.71)   \< 0.0001   5.5    0.13
  Heart Dis                                 1.70                      (1.51-1.91)                 \< 0.0001                                       1.95   (1.74-2.17)   \< 0.0001   14.5   0.09
  CBVD                                      1.48                      (1.18-1.86)                 0.001                                           1.39   (1.12-1.72)   0.003       -6.2   0.70
  CVD                                       1.66                      (1.49-1.84)                 \< 0.0001                                       1.79   (1.63-1.96)   \< 0.0001   7.8    0.29
  Model 3                                                                                                                                                                                 
  All-cause                                 1.47                      (1.39-1.55)                 \< 0.0001                                       1.55   (1.47-1.63)   \< 0.0001   5.5    0.15
  Heart Dis                                 1.62                      (1.44-1.82)                 \< 0.0001                                       1.80   (1.60-2.03)   \< 0.0001   11.2   0.21
  CBVD                                      1.35                      (1.04-1.75)                 0.023                                           1.40   (1.12-1.75)   0.003       3.4    0.85
  CVD                                       1.57                      (1.40-1.75)                 \< 0.0001                                       1.68   (1.52-1.86)   \< 0.0001   7.4    0.35
  Model 4                                                                                                                                                                                 
  All-cause                                 1.42                      (1.35-1.49)                 \< 0.0001                                       1.50   (1.42-1.58)   \< 0.0001   5.6    0.15
  Heart Dis                                 1.58                      (1.33-1.69)                 \< 0.0001                                       1.65   (1.48-1.89)   \< 0.0001   4.4    0.19
  CBVD                                      1.28                      (0.99-1.66)                 0.06                                            1.33   (1.06-1.66)   0.013       3.9    0.83
  CVD                                       1.46                      (1.31-1.63)                 \< 0.0001                                       1.58   (1.42-1.75)   \< 0.0001   8.2    0.32
  Model 5 - in those without baseline CVD                                                                                                                                                 
  All-cause                                 1.32                      (1.23-1.41)                 \< 0.0001                                       1.40   (1.32-1.50)   \< 0.0001   6.1    0.19
  Heart Dis                                 1.22                      (1.03-1.45)                 0.019                                           1.43   (1.21-1.69)   \< 0.0001   17.2   0.19
  CBVD                                      1.24                      (0.93-1.67)                 0.137                                           1.41   (1.10-1.82)   0.008       13.7   0.53
  CVD                                       1.22                      (1.04-1.43)                 0.017                                           1.45   (1.26-1.67)   \< 0.0001   18.9   0.08

Excess HR = \[(HR in female/HR in male) - 1\] × 100. Significant test was estimated based on sex × DM interaction. *P*-values were given by Cox regression models. Model 1: Adjusted for age and race/ethnicity (NH-White, NH-Black, Hispanics, and all other race group); Model 2: Adjusted for Model 1 plus education; Model 3: Adjusted for Model 2 plus smoking, alcohol, and physical activity status; Model 4: Adjusted for Model 2 plus smoking, alcohol, physical activity status, hypertension. DM: Diabetes mellitus; CBVD: Cerebrovascular disease; CVD: Cardiovascular disease.

Females appeared to have a higher HRs of DM for mortality from all-cause, heart disease and CVD than males. However, the increased HRs in females became non-significant after adjusting for age, race/ethnicity and education (Model 2), adjusting for behavior factors (Model 3), adjusting hypertension (Model 4), and excluding those who had heart disease and stroke at baseline (Model 5).

Proportions of antidiabetic medication usage in patients with DM
----------------------------------------------------------------

Table [4](#T4){ref-type="table"} shows that in males, 10% of patients with DM did not use any antidiabetic medications, and 38.1% of DM patients used antidiabetic monotherapy, and 51.9% used ≥ 2 antidiabetic medications. The corresponding values of the prevalence of those who did not use any antidiabetic medication, those who used 1 only (*i.e*., monotherapy), and those who used ≥ 2 were 10.3%, 40.4% and 49.4% in females respectively. Of those with monotherapy in males, 37.2% patients used insulin, followed by metformin (27.3%), sulfonylureas (25.9%) and others (9.6%). The most common three monotherapies in females were metformin (33.2%), insulin (33.0%), and sulfonylureas (21.9%), (gender differences: *P* = 0.008). Among patients with combined antidiabetic medication therapies, the most frequent combination was metformin and sulfonylureas (20.1% in males, and 21.9% in females). No significant differences in the proportions of combined therapies between males and females were observed (*P* = 0.42).

###### 

Proportion of antidiabetic medication use in patients with diabetes by gender

                                 **Male**   **Female**                    
  ------------------------------ ---------- ------------ ------- -------- -------
  By groups                                                               
  Monotherapy                    38.11      (1.19)       40.36   (1.06)   0.291
  Combination                    51.89      (1.27)       49.38   (1.10)   
  No drug                        10.00      (0.83)       10.26   (0.66)   
  Monotherapy                                                             
  Biguanides (Metformin)         27.32      (1.89)       33.24   (1.57)   0.008
  SU                             25.86      (1.72)       21.88   (1.34)   
  Insulin                        37.20      (1.85)       33.01   (1.42)   
  Others                         9.63       (1.16)       11.87   (0.95)   
  Combination                                                             
  Metformin + SU                 20.05      (1.34)       21.94   (1.10)   0.422
  TZD + Any (insulin excluded)   13.56      (1.25)       13.11   (0.87)   
  Insulin + Any (TZD excluded)   15.25      (1.38)       16.91   (1.07)   
  Metformin + SU + TZD           7.72       (0.86)       6.75    (0.69)   
  Metformin + SU + Insulin       6.89       (0.87)       4.97    (0.61)   
  Any other combinations         36.52      (1.85)       36.32   (1.44)   

*P* values were given by *χ*^2^ test. Others include alpha glucosidase inhibitors, meglinitides, dipeptidyl peptidase 4 inhibitors, amylin analogs, and incretin mimetics. TZD: Thiazolidinedione; SU: Sulfonylureas; SEP: Standard error of proportion.

Hazard ratios of antidiabetic medication use for risk of mortality
------------------------------------------------------------------

Table [5](#T5){ref-type="table"} shows that after adjustment for key covariates, patients with treatment of antidiabetic medication *vs* those without had 7% lower risk of mortality from all-cause (HR = 0.93, 95%CI: 0.73-1.18, *P* = 0.56, Model 2) and 4% lower risk from CVD (HR = 0.96, 95%CI: 0.60-1.54, *P* = 0.87, Model 2), although these associations did not reach statistical significance. However, DM patients with metformin monotherapy had a significantly decreased risk of all-cause mortality (HR = 0.55, 95%CI: 0.38-0.80, *P* = 0.002, Model 2), but those with insulin monotherapy showed an increased risk of all-cause mortality (HR = 1.71, 95%CI: 1.31-2.24, *P* \< 0.0001, Model 2). A protective but non-significant effect of the treatment of antidiabetic medications (except for sulfonylureas and insulin use) on CVD mortality was observed.

###### 

Multivariate adjusted hazard ratios (HR, 95%CI) of antidiabetic medication use for mortality from all-cause and cardiovascular disease in patients with diabetes

                                    **All-cause mortality**   **Mortality from CVD**                                                                                                         
  --------------------------------- ------------------------- ------------------------ ---------- ------ ------------- ----------- ------ ------------- ------- ------ ------------- ------- --
  Medication use *vs* no-use        0.87                      (0.68-1.11)              0.251      0.93   (0.73-1.18)   0.556       0.88   (0.54-1.44)   0.613   0.96   (0.60-1.54)   0.873   
  Monotherapy (ref: Non-drug use)                                                                                                                                                            
  Biguanides (Metformin)            0.53                      (0.36-0.77)              0.001      0.55   (0.38-0.80)   0.002       0.82   (0.42-1.61)   0.564   0.87   (0.45-1.68)   0.681   
  SU                                0.89                      (0.66-1.21)              0.456      0.91   (0.67-1.23)   0.529       1.10   (0.66-1.83)   0.716   1.11   (0.67-1.84)   0.696   
  Insulin                           1.65                      (1.26-2.16)              \< 0.001   1.71   (1.31-2.24)   \< 0.0001   1.51   (0.86-2.66)   0.153   1.58   (0.92-2.70)   0.094   
  Combination                                                                                                                                                                                
  Metformin + SU                    0.75                      (0.55-1.01)              0.059      0.81   (0.60-1.10)   0.168       0.77   (0.41-1.43)   0.403   0.87   (0.48-1.57)   0.632   
  TZD + Any (insulin excluded)      0.87                      (0.60-1.26)              0.468      0.98   (0.67-1.42)   0.905       0.43   (0.23-0.82)   0.011   0.52   (0.28-0.98)   0.042   
  Insulin + Any (TZD excluded)      1.27                      (0.90-1.78)              0.171      1.33   (0.94-1.86)   0.103       1.37   (0.69-2.72)   0.365   1.45   (0.75-2.81)   0.264   
  Metformin + SU + TZD              0.40                      (0.25-0.65)              \< 0.001   0.43   (0.27-0.70)   0.001       0.54   (0.24-1.18)   0.120   0.58   (0.27-1.25)   0.164   
  Metformin + SU + Insulin          0.64                      (0.41-1.01)              0.053      0.67   (0.43-1.05)   0.080       0.75   (0.44-1.29)   0.293   0.80   (0.47-1.37)   0.418   
  Other combination                 0.63                      (0.46-0.86)              0.004      0.68   (0.50-0.93)   0.016       0.59   (0.31-1.09)   0.091   0.64   (0.35-1.19)   0.157   

Others: Include alpha glucosidase inhibitors, meglinitides, dipeptidyl peptidase 4 inhibitors, amylin analogs, and incretin mimetics. *P* values were given by Cox regression models. Model 1: Adjusted for age, sex, race/ethnicity, and survey year; Model 2: Adjusted for Model 1 plus anti-hypertension and anti-hyperlipidemia drugs. TZD: Thiazolidinedione; SU: Sulfonylureas.

In patients with DM, a combination of metformin, sulfonylureas and thiazolidinedione showed a significantly reduced risk of all-cause mortality compared to those who did not use a combination therapy (HR = 0.43, 95%CI: 0.27-0.70, *P* = 0.001, Model 2 in Table [5](#T5){ref-type="table"}). A significantly reduced risk of all-cause mortality was observed as well in patients with any other combined drug therapies (0.68, 0.50-0.93, *P* = 0.016, Model 2). No significant association between combination medication use and risk of CVD mortality was observed for DM patients with or without combination therapies, except for those with thiazolidinedione plus any other antidiabetic medications (excluding insulin) (0.52, 0.28-0.98, *P* = 0.042).

Table [6](#T6){ref-type="table"} shows that DM patients with insulin monotherapy showed an increased risk of heart disease mortality than those without insulin monotherapy (1.91, 1.12-3.26, *P* = 0.018, Model 2). A combination of metformin, sulfonylureas and insulin was significantly and negatively associated with heart disease mortality (0.35, 0.20-0.62, *P* \< 0.0001, Model 2). No statistical significance in mortality from CBVD was observed in DM patients with or without medication (neither monotherapy nor combinations).

###### 

Multivariate adjusted hazard ratios (HR, 95%CI) of antidiabetic medication use for mortality from heart disease and cerebrovascular disease in patients with diabetes

                                 **Heart disease mortality**   **Cerebrovascular disease (CBVD) mortality**                                                                                                         
  ------------------------------ ----------------------------- ---------------------------------------------- ------- ------ ------------- ----------- ------ ------------- ------- ------ ------------- ------- -- --
  Medication use *vs* no-use     1.01                          (0.62-1.65)                                    0.982   1.08   (0.67-1.74)   0.741       0.58   (0.19-1.78)   0.339   0.67   (0.23-1.95)   0.457      
  Monotherapy                                                                                                                                                                                                       
  Biguanides (Metformin)         0.80                          (0.38-1.67)                                    0.550   0.83   (0.40-1.70)   0.608       0.94   (0.22-4.01)   0.938   1.20   (0.30-4.82)   0.792      
  SU                             1.26                          (0.76-2.11)                                    0.373   1.27   (0.76-2.13)   0.364       0.71   (0.23-2.24)   0.560   0.76   (0.25-2.34)   0.629      
  Insulin                        1.85                          (1.06-3.24)                                    0.031   1.91   (1.12-3.26)   0.018       0.60   (0.16-2.23)   0.445   0.71   (0.23-2.21)   0.547      
  Combined                                                                                                                                                                                                          
  Metformin + SU                 0.82                          (0.41-1.67)                                    0.586   0.91   (0.47-1.80)   0.794       0.59   (0.14-2.47)   0.472   0.71   (0.17-2.94)   0.632      
  TZD + Any (insulin excluded)   0.55                          (0.28-1.08)                                    0.082   0.68   (0.35-1.30)   0.242       0.14   (0.02-1.18)   0.070   0.15   (0.02-1.32)   0.088      
  Insulin + Any (TZD excluded)   1.79                          (0.89-3.61)                                    0.103   1.85   (0.94-3.64)   0.074       0.44   (0.13-1.53)   0.196   0.50   (0.15-1.66)   0.257      
  Metformin + SU + TZD           0.61                          (0.27-1.40)                                    0.245   0.65   (0.30-1.42)   0.280       0.34   (0.04-2.83)   0.316   0.41   (0.04-3.95)   0.438      
  Metformin + SU + Insulin       0.33                          (0.19-0.59)                                    0.000   0.35   (0.20-0.62)   \< 0.0001   1.66   (0.55-5.02)   0.368   1.91   (0.64-5.73)   0.245      
  Other combinations             0.71                          (0.37-1.37)                                    0.307   0.78   (0.42-1.47)   0.444       0.28   (0.06-1.31)   0.106   0.31   (0.07-1.41)   0.129      

Others: Include alpha glucosidase inhibitors, meglinitides, dipeptidyl peptidase 4 inhibitors, amylin analogs, and incretin mimetics. *P* values were given by Cox regression models. Model 1: Adjusted for age, sex, race/ethnicity, and survey year; Model 2: Adjusted for Model 1 plus anti-hypertension and anti-hyperlipidemia drugs. TZD: Thiazolidinedione; SU: Sulfonylureas.

DISCUSSION
==========

The present study, using data from one of the largest national health survey systems and multiple linkage files, examined the burden of DM and its impact on CVD and all-cause mortality among adults in the United States. The study adds new evidence to the body of scientific literatures regarding antidiabetic medication profiles and health outcomes in patients with DM. The main findings show that: (1) the prevalence of DM significantly increased in all age groups for males and females in the last decade; (2) patients with DM had 1.47 to 1.62 times higher risk of death from all-cause and CVD in males, and 1.55 to 1.68 times higher in females compared to those without DM; (3) about 40% of patients with DM used antidiabetic monotherapy, and about 50% used combined antidiabetic therapy, however 10% of patient with DM did not use any medication in both males and females; and (4) in patients with DM, using metformin monotherapy or a combined therapy of metformin with other antidiabetic medications showed a significantly reduced risk of all-cause mortality. This protective association remained significant after adjustment for age, sex, race/ethnicity, survey year, antihypertensive drug, and anti-dyslipidemia medication use.

The present study confirmed an increased prevalence of DM in the last decade in the United States This finding is consistent with previous reports\[[@B1]-[@B4]\], and provides new evidence at the national level. Several factors may contribute to the increased rates. Of them, an increased prevalence of obesity across the nation may contribute to the increased trend of DM. We analyzed obesity rate using the same NHIS data. Figure [4](#F4){ref-type="fig"} depicts a positive correlation trend between the prevalence of obesity and DM between 2000 and 2009 by four age groups in males (Figure [4A](#F4){ref-type="fig"}) and in females (Figure [4B](#F4){ref-type="fig"}) between 2000 and 2009. The highest correlation coefficient (r) was shown in ages 18-54 (*r* = 0.91, *P* \< 0.001) in males, and ages 18-54 (*r* = 0.95, *P* \< 0.001), and 55-64 (*r* = 0.95, *P* \< 0.001) in females. Given the well-known pathophysiological mechanisms of obesity and risk of DM, this finding suggests that control of obesity would play a pivotal role in stopping the unwelcome trends of DM. In addition, females aged 55-74 have a greater increased trend of DM than males (Figure [1B](#F1){ref-type="fig"}). Although it is unclear why there is a notable increase in this age group for females, changes in female hormone at pre- and post-menopausal ages may partly explain this gender difference in the risk of DM and other chronic diseases\[[@B5],[@B7],[@B17]-[@B21]\]. Data from the Women's Health Initiative Hormone Trial suggest that combined therapy with estrogen and progestin reduces the incidence of DM\[[@B21]\].

![Chnages in obesity rates and its corelation with diabetes rates. A: Correlation between prevalence of obesity and diabetes by age in males, United States NHIS 2000-2009; B: Correlation between prevalence of obesity and diabetes by age in females, United States NHIS 2000-2009. NHIS: National Health Interview Surveys; DM: Diabetes mellitus.](WJD-7-449-g004){#F4}

As demonstrated in several studies, we observed an excess relative risk (*i.e*., hazard ratio) of DM for all-cause and heart disease in females *vs* males. However, this excess risk became non-significant after adjustment for key covariates. Findings using data from the earlier Framingham Heart Study (FHS) surveys (1970s and 1980s) demonstrated a significant excess risk of recurrent myocardial infarction and fatal coronary heart disease for women with DM *vs* men with DM\[[@B22],[@B23]\]. Our non-significant results are not consistent with the previous report. It may be attributable to the different datasets we used from the FHS. For example, the majority of participants in FHS were white middle class individuals who may have different risk profiles from minorities and people with lower social status. Furthermore, a decreased relative risk of DM for CVD in recent generations has been observed because of early diagnosis and disease prevention as well as more advanced treatment than two or three decades ago. Nevertheless, this relatively higher risk of DM for coronary heart disease in women *vs* men should be still taken into consideration in CVD risk assessment and disease prevention. In the study, among 5 preventable CVD risk factors that we examined, 4 (percent of individuals with lower socioeconomic status, assessed by education level, the proportion of individuals who were physically inactive, the proportion of individuals with obesity, and the proportion of individuals who had hypertension) were significantly higher in females than males, although males had a higher smoking rate than females (Table [7](#T7){ref-type="table"}). These risk factors differences may partly explain the relative risk difference between genders. It is clear further studies are needed to assess the gender differences, including studies of the established and emerging risk predictors\[[@B15],[@B24]-[@B28]\].

###### 

Age-race-adjusted rates of five selected predicators for cardiovascular disease in patients with diabetes at baseline, 2000-2009 National Health Interview Surveys

                          **Patients with DM at baseline**                             
  ----------------------- ---------------------------------- -------- ------- -------- -----------
  Education                                                                            
  Less than HS            21.53                              (0.50)   24.82   (0.47)   \< 0.0001
  HS Graduated            28.44                              (0.59)   30.61   (0.55)   0.0100
  ≥ College               50.03                              (0.60)   44.57   (0.56)   \< 0.0001
  Smoking status                                                                       
  No smoker               40.92                              (0.58)   61.60   (0.53)   \< 0.0001
  Former smoker           36.03                              (0.58)   17.81   (0.49)   \< 0.0001
  Current smoker          23.05                              (0.46)   20.59   (0.35)   \< 0.0001
  Exercise                                                                             
  Inactive                42.80                              (0.63)   49.34   (0.62)   \< 0.0001
  Insufficiently active   26.88                              (0.52)   27.98   (0.49)   0.1000
  Sufficiently active     30.32                              (0.61)   22.68   (0.47)   \< 0.0001
  BMI, kg/m^2^                                                                         
  Overweight              34.21                              (0.55)   25.82   (0.46)   \< 0.0001
  Obesity                 47.13                              (0.60)   53.88   (0.51)   \< 0.0001
  Medical condition                                                                    
  Hypertension            52.54                              (0.58)   54.55   (0.46)   0.0100

Education ≥ College including those with associate degrees. Overweight: Body mass index (BMI) 25 to 29.9 kg/m^2^. Obesity: BMI ≥ 30 kg/m^2^. *P* values were given by *χ*^2^ test. HS: High school.

The present study provides new evidence of the patterns of antidiabetic medicine usage and their impact on all-cause and CVD mortalities in patients with DM. Treatments with metformin, insulin, and sulfonylureas were the top three medications in the study population. More than one third of patients took insulin, which is commonly given to patients either for a short-term use because of significantly out of control serum glucose, or for long-term glucose control because their DM has progressed over many years (commonly between 10 and 20 years) and their pancreas can no longer make enough insulin to respond to other glucose-lowering medications\[[@B5],[@B29]\]. Similar to previous studies, findings from the present study suggest a significant protective effect on all-cause mortality, and a protective effect on CVD mortality for those using metformin or metformin combined with other glucose-lowering medications. Metformin, a class of medications known as "biguanides" and a first-line agent for type 2 DM (T2DM) pharmacotherapy, is one of the most prescribed drugs worldwide\[[@B30]\]. It has been suggested that the potential mechanisms by which metformin reduces the risk of mortality is lowering blood glucose by reducing hepatic glucose output, decreasing intestinal glucose absorption, and controlling body weight by decreasing food intake\[[@B30]-[@B32]\], The mechanism of the cardiovascular effect of metformin was reported to improve lipoprotein profiles in diabetic patients by decreasing plasma concentrations of free fatty acid, triglycerides, total cholesterol and LDL cholesterol and increased HDL cholesterol\[[@B30]\]. Meanwhile, all-cause mortality includes deaths from cancer as well. Several studies have shown a significant risk reduction in cancer incidence and mortality among diabetic patients on metformin use relative to other antidiabetic drugs use\[[@B33]\]. Furthermore, in considering that biguanides demonstrate a better safety profile than most oncology drugs in current anticancer drug use, nonconventional routes for administering diabetobiguanides for cancer treatment has been suggested\[[@B34]\]. Findings from the present study support the current knowledge of metformin therapy in the reduction of CVD and total mortality, although further studies are needed in detail on its specific association with CVD and cancers.

In addition to the strength of using a large-scale sample size, the present study has several other advantages. First, using the NHIS-Mortality Linked Files, we were able to test the association between DM and risk of outcomes prospectively. Second, by using NHIS-MEPS linkage Files, we were able to test the patterns of medications which paves the way for us to further test more details on the association between pharmacotherapy and disease outcomes using a nationally representative dataset.

Similar to any study, however, the present study has several limitations. First, we were unable to classify whether a patient with DM was type 1 DM (T1DM) or T2DM because the NHIS data did not collect the information. Therefore, findings from the study cannot be applied to interpret risk differences between T1DM and T2DM. However, although T1DM can occur at any age, it is most often diagnosed in children, adolescents, or young adults. The NHIS's participants were aged 18 and older. Furthermore, it is well-known that the majority of total DM are T2DM in general population, we may be able to assume the majority DM cases in the NHIS data were T2DM. Second, baseline predictors were measured once only, that any changes in the study variables after baseline may affect the prospective estimates of the associations between baseline predictors and health outcomes. Findings of the study should be on the basis of the hypothesis that these changes, if any, were randomized across all participants, so that a potential time-varying bias would be small when a study uses a large-scale sample size\[[@B35]\]. Third, participants' medical conditions at baseline were self-reported physician-diagnosis of disease (hypertension, CHD, stroke and DM), therefore possible recall bias may occur. However, the recall bias might have a relatively small effect, because the use of self-reports of physician-diagnosis of disease have been confirmed as a valid approach in large-scale population health surveys in the United States\[[@B36],[@B37]\]. Fourth, the NHIS did not have data on participants' physical exams and laboratory tests (*i.e*., without exact blood pressure measures, and measures from serum lipids and metabolic biomarkers), which may not only lead to underestimate the prevalence of hypertension and DM, but also limit us to quantitatively estimate the association between antidiabetic drug use and changes in serum HbA1c (a biomarker of glycaemia control status in diabetic patients) and lipid profiles, and their impacts on the study outcomes. Therefore, the findings of the study provide a relatively conservative estimate of the burdens of disease. Fifth, we were unable to test subgroups of antidiabetic drugs' effects on the study outcomes, such as the subgroups of sulfonylureas, because the detail data was not available from NHIS-MESP Linkage File. Sixth, in multivariate analysis, we cannot always be able to control adequately for confounding factors. We may not even know about them and chance cannot be discarded although it is highly unlikely.

Despite the limitations discussed the above, three clear and important conclusions follow the present study. First, the prevalence of DM significantly increased in all age groups in the past decade, with specific increase in females aged 55-74 compared to males. Second, DM is a significant predictor for mortality from all-cause and CVD in both genders, with a slightly higher excess relative risk in females *vs* males. Third, about 10% of patients with DM do not receive antidiabetic therapy. DM patients who received metformin monotherapy or combination of metformin with other antidiabetic medications (except insulin) showed a significant protective effect on all-cause mortality.
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